Loading…
Loading…
EQUITY / NASDAQ · XNCM
Edesa Biotech, Inc.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗3.86 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 3.86 USD · Volume 18,463
681 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 3 | Prior year | Change |
|---|---|---|---|
| Operating profit | -5,519,549 USD | — | — |
| Net income | -5,407,611 USD | — | — |
| Cash and cash equivalents | 10,300,000 USD | — | — |
| Total equity | 8,811,154 USD | — | — |
| Total assets | 12,721,195 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 304/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 310/01/2025 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 303/31/2026 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 210/01/2025 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2026 / Quarter 110/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 309/30/2025 – 09/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 10,300,000 USD | — | — | 10,000,000 USD | — | — | 12,100,000 USD | — |
| Net incomeIncome statement | -5,407,611 USD | -11,873,612 USD | — | -4,218,332 USD | -6,466,001 USD | — | -2,247,669 USD | — |
| Operating profitIncome statement | -5,519,549 USD | -12,157,926 USD | — | -4,296,994 USD | -6,638,377 USD | — | -2,341,383 USD | — |
| Total assetsBalance sheet | 12,721,195 USD | — | — | 12,384,738 USD | — | — | 14,710,442 USD | 13,530,518 USD |
| Total equityBalance sheet | 8,811,154 USD | — | 10,196,817 USD | 10,196,817 USD | — | 13,954,279 USD | 13,954,279 USD | 12,451,982 USD |
| Financing cash flowCash flow statement | — | 6,793,376 USD | — | — | 3,346,439 USD | — | 3,355,419 USD | — |
| Operating cash flowCash flow statement | — | -7,186,629 USD | — | — | -4,103,956 USD | — | -2,087,334 USD | — |
| Report source | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 05/14/2026 | Open report ↗ Published: 05/14/2026 | Open report ↗ Published: 05/14/2026 | Open report ↗ Published: 02/13/2026 | Open report ↗ Published: 08/13/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.